TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

To gain a better insight into Eisai’s current pipeline, its disease areas of importance and what Eisai are conducting beyond therapy development to tackle diseases we spoke with Gary Hendler.